Graybug Vision (GRAY) Competitors

$0.59 0.00 (-0.24%)

As of 05/1/2026

GRAY vs. DCOY, VCNX, ORGS, ATXI, and CANF

Should you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include Decoy Therapeutics (DCOY), Vaccinex (VCNX), Orgenesis (ORGS), Avenue Therapeutics (ATXI), and Can-Fite BioPharma (CANF).

How does Graybug Vision compare to Decoy Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Graybug Vision (NASDAQ:GRAY) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

: Graybug Vision's return on equity of -77.61% beat Decoy Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Decoy Therapeutics N/A -534.45% -239.74%
Graybug Vision N/A -77.61% -71.34%
: Decoy Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
: Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 413.70%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Graybug Vision.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Decoy Therapeutics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Graybug Vision
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Decoy Therapeutics has higher earnings, but lower revenue than Graybug Vision. Graybug Vision is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Decoy Therapeutics N/A N/A -$12.52M -$406.89 N/A
Graybug Vision $426.96M 0.00 -$35.60M -$24.23 N/A
: 11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 0.3% of Decoy Therapeutics shares are owned by insiders. Comparatively, 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: In the previous week, Graybug Vision's average media sentiment score of 0.84 beat Decoy Therapeutics' score of 0.00 indicating that Graybug Vision is being referred to more favorably in the news media.
Company Overall Sentiment
Decoy Therapeutics Neutral
Graybug Vision Positive

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-534.45%	-239.74%
Graybug Vision	N/A	-77.61%	-71.34%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$406.89	N/A
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Graybug Vision	Positive

Summary

Graybug Vision beats Decoy Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Graybug Vision compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

: 50.1% of Vaccinex shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 51.5% of Vaccinex shares are held by insiders. Comparatively, 7.9% of Graybug Vision shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Vaccinex has higher earnings, but lower revenue than Graybug Vision. Graybug Vision is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vaccinex $388K 7.04 -$20.25M -$48.27 N/A
Graybug Vision $426.96M 0.00 -$35.60M -$24.23 N/A
: Vaccinex has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
: In the previous week, Vaccinex had 2 more articles in the media than Graybug Vision. MarketBeat recorded 2 mentions for Vaccinex and 0 mentions for Graybug Vision. Graybug Vision's average media sentiment score of 0.84 beat Vaccinex's score of 0.72 indicating that Graybug Vision is being referred to more favorably in the news media.
Company Overall Sentiment
Vaccinex Positive
Graybug Vision Positive
: Vaccinex's return on equity of 0.00% beat Graybug Vision's return on equity.
Company Net Margins Return on Equity Return on Assets
Vaccinex N/A N/A -383.58%
Graybug Vision N/A -77.61% -71.34%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.04	-$20.25M	-$48.27	N/A
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A

Company	Overall Sentiment
Vaccinex	Positive
Graybug Vision	Positive

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Graybug Vision	N/A	-77.61%	-71.34%

Summary

Vaccinex beats Graybug Vision on 7 of the 12 factors compared between the two stocks.

How does Graybug Vision compare to Orgenesis?

Graybug Vision (NASDAQ:GRAY) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

: 49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by insiders. Comparatively, 5.7% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Graybug Vision has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Graybug Vision $426.96M 0.00 -$35.60M -$24.23 N/A
Orgenesis $662K 4.65 -$55.36M -$11.51 N/A
: Graybug Vision has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.07, suggesting that its stock price is 207% more volatile than the S&P 500.
: In the previous week, Graybug Vision's average media sentiment score of 0.84 beat Orgenesis' score of 0.00 indicating that Graybug Vision is being referred to more favorably in the media.
Company Overall Sentiment
Graybug Vision Positive
Orgenesis Neutral
: Graybug Vision has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Graybug Vision's return on equity.
Company Net Margins Return on Equity Return on Assets
Graybug Vision N/A -77.61% -71.34%
Orgenesis -3,827.81% N/A -130.18%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A
Orgenesis	$662K	4.65	-$55.36M	-$11.51	N/A

Company	Overall Sentiment
Graybug Vision	Positive
Orgenesis	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Graybug Vision	N/A	-77.61%	-71.34%
Orgenesis	-3,827.81%	N/A	-130.18%

Summary

Graybug Vision beats Orgenesis on 7 of the 12 factors compared between the two stocks.

How does Graybug Vision compare to Avenue Therapeutics?

Graybug Vision (NASDAQ:GRAY) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

: 49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Avenue Therapeutics has lower revenue, but higher earnings than Graybug Vision. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Graybug Vision $426.96M 0.00 -$35.60M -$24.23 N/A
Avenue Therapeutics N/A N/A -$10.38M -$0.94 N/A
: Graybug Vision has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500.
: In the previous week, Graybug Vision's average media sentiment score of 0.84 beat Avenue Therapeutics' score of 0.00 indicating that Graybug Vision is being referred to more favorably in the media.
Company Overall Sentiment
Graybug Vision Positive
Avenue Therapeutics Neutral
: Graybug Vision's return on equity of -77.61% beat Avenue Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Graybug Vision N/A -77.61% -71.34%
Avenue Therapeutics N/A -471.57% -296.50%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.94	N/A

Company	Overall Sentiment
Graybug Vision	Positive
Avenue Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Graybug Vision	N/A	-77.61%	-71.34%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Summary

Graybug Vision beats Avenue Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Graybug Vision compare to Can-Fite BioPharma?

Graybug Vision (NASDAQ:GRAY) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

: Can-Fite BioPharma's return on equity of 0.00% beat Graybug Vision's return on equity.
Company Net Margins Return on Equity Return on Assets
Graybug Vision N/A -77.61% -71.34%
Can-Fite BioPharma N/A N/A N/A
: Can-Fite BioPharma has lower revenue, but higher earnings than Graybug Vision. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Graybug Vision $426.96M 0.00 -$35.60M -$24.23 N/A
Can-Fite BioPharma $405K 5.66 -$7.63M -$35.80 N/A
: 49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 7.9% of Graybug Vision shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.
: Can-Fite BioPharma has a consensus price target of $65.00, indicating a potential upside of 1,757.14%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Graybug Vision.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Graybug Vision
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Can-Fite BioPharma
0 Sell rating(s)

2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.33
: In the previous week, Can-Fite BioPharma had 2 more articles in the media than Graybug Vision. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 0 mentions for Graybug Vision. Graybug Vision's average media sentiment score of 0.84 beat Can-Fite BioPharma's score of 0.34 indicating that Graybug Vision is being referred to more favorably in the media.
Company Overall Sentiment
Graybug Vision Positive
Can-Fite BioPharma Neutral

Company	Net Margins	Return on Equity	Return on Assets
Graybug Vision	N/A	-77.61%	-71.34%
Can-Fite BioPharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A
Can-Fite BioPharma	$405K	5.66	-$7.63M	-$35.80	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Can-Fite BioPharma	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Overall Sentiment
Graybug Vision	Positive
Can-Fite BioPharma	Neutral

Summary

Can-Fite BioPharma beats Graybug Vision on 8 of the 15 factors compared between the two stocks.

Get Graybug Vision News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRAY vs. The Competition

Export

Metric	Graybug Vision	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$925K	$886.55M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	-0.34	1.71	29.25	27.07
Price / Sales	0.00	120.63	504.68	73.47
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	0.35	7.60	9.67	6.69
Net Income	-$35.60M	-$4.80M	$3.55B	$332.64M
7 Day Performance	-0.25%	-0.05%	1.70%	2.01%
1 Month Performance	0.62%	5.50%	5.62%	9.19%
1 Year Performance	-66.37%	30.96%	34.42%	39.59%

Graybug Vision Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRAY Graybug Vision	N/A	$0.59 -0.2%	N/A	N/A	$925K	$426.96M	N/A	27	Gap Up High Trading Volume
DCOY Decoy Therapeutics	1.2234 of 5 stars	$5.91 -2.4%	$30.00 +408.0%	N/A	$3.22M	N/A	N/A	20	Gap Down
VCNX Vaccinex	N/A	$1.00 +28.7%	N/A	N/A	$2.60M	$388K	N/A	40	Gap Up
ORGS Orgenesis	N/A	$0.40 flat	N/A	N/A	$2.07M	$662K	N/A	150	Gap Up
ATXI Avenue Therapeutics	N/A	$0.61 +10.5%	N/A	N/A	$2.00M	N/A	0.03	4	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRAY) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Graybug Vision (GRAY) Competitors

GRAY vs. DCOY, VCNX, ORGS, ATXI, and CANF

How does Graybug Vision compare to Decoy Therapeutics?

Summary

How does Graybug Vision compare to Vaccinex?

Summary

How does Graybug Vision compare to Orgenesis?

Summary

How does Graybug Vision compare to Avenue Therapeutics?

Summary

How does Graybug Vision compare to Can-Fite BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAY vs. The Competition

Graybug Vision Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Graybug Vision (GRAY) Competitors

GRAY vs. DCOY, VCNX, ORGS, ATXI, and CANF

How does Graybug Vision compare to Decoy Therapeutics?

Summary

How does Graybug Vision compare to Vaccinex?

Summary

How does Graybug Vision compare to Orgenesis?

Summary

How does Graybug Vision compare to Avenue Therapeutics?

Summary

How does Graybug Vision compare to Can-Fite BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAY vs. The Competition

Graybug Vision Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools